SecurityBVSN / BroadVision, Inc. (111412706)
Institutional Owners22 (1 N-Q Owners)
Institutional Shares275,980 - 5.52% (ex. N-Q)
Common Stock Shares Outstanding4,997,000 shares (as of 2018-03-31)
Institutional Value$ 751,000 USD (ex. N-Q)

Institutional Stock Ownership and Shareholders

BVSN / BroadVision, Inc. Institutional Ownership

BroadVision, Inc. (NASDAQ:BVSN) has 22 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 275,980 shares. Largest shareholders include Dimensional Fund Advisors Lp, Renaissance Technologies LLC, Vanguard Group Inc, California Public Employees Retirement System, BlackRock Inc., Bank Of America Corp /de/, Ladenburg Thalmann Financial Services Inc, Fifth Third Bancorp, Deutsche Bank Ag\, and Marino, Stram & Associates Llc.
BroadVision, Inc. (NASDAQ:BVSN) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Embed this chart! (it updates automatically)
<a href="https://fintel.io/so/us/bvsn"><img src="https://images.fintel.io/us-bvsn-so.png" alt="BVSN / BroadVision, Inc. Institutional Ownership"><a>

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-05-04 13F-HR SAN FRANCISCO SENTRY INVESTMENT GROUP (CA) 1 1 0.00 0 0
2018-05-10 13F-HR CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM 13,100 12,343 -5.78 47 33 -29.79
2018-05-15 13F-HR Marino, Stram & Associates Llc 10 10 0.00 0 0
2018-05-14 13F-HR MORGAN STANLEY 1 0 -100.00 0 0
2018-05-03 13F-HR Cowen Prime Services LLC 0 4 0 0
2018-05-14 13F-HR Renaissance Technologies LLC 80,300 81,400 1.37 289 227 -21.45
2018-04-13 13F-HR BANK OF MONTREAL /CAN/ 1 1 0.00 0 0
2018-05-15 13F-HR BANK OF AMERICA CORP /DE/ 342 342 0.00 1 1 0.00
2018-02-14 13F-HR BRIDGEWAY CAPITAL MANAGEMENT INC 72,749 0 -100.00 287 0 -100.00
2018-05-15 13F-HR VANGUARD GROUP INC 71,416 71,416 0.00 257 193 -24.90
2018-05-09 13F-HR IFP Advisors, Inc 4 4 0.00 0 0
2018-05-15 13F-HR FIFTH THIRD BANCORP 54 54 0.00 0 0
2018-05-11 13F-HR DIMENSIONAL FUND ADVISORS LP 109,373 109,373 0.00 394 295 -25.13
2018-05-10 13F-HR Stratos Wealth Partners, LTD. 1 1 0.00 0 0
2018-02-01 13F-HR Nationwide Fund Advisors 530 0 -100.00 2 0 -100.00
2018-05-02 13F-HR WELLS FARGO & COMPANY/MN 1 1 0.00 0 0
2018-05-15 13F-HR UBS Group AG 619 0 -100.00 2 0 -100.00
2018-04-20 13F-HR FIRST MANHATTAN CO 2 2 0.00 0 0
2018-05-15 13F-HR DEUTSCHE BANK AG\ 33 34 3.03 0 0
2018-05-09 13F-HR BlackRock Inc. 885 885 0.00 3 2 -33.33
2018-05-15 13F-HR Advisor Group, Inc. 8 8 0.00 0 0
2018-05-15 13F-HR LADENBURG THALMANN FINANCIAL SERVICES INC 85 85 0.00 0 0
2018-05-18 13F-HR/A ROYAL BANK OF CANADA 6 6 0.00 0 0
2018-05-11 13F-HR NORTHERN OAK WEALTH MANAGEMENT INC 9 9 0.00 0 0
2018-02-28 N-Q Ishares Trust (see advisory)
2018-04-30 13F-HR Camarda Financial Advisors, LLC 1 0

Form N-Q Advisory - Experimental Feature Here!

We have recently started to include coverage of N-Q filers in our ownership database. N-Q forms are unstructured and difficult for machines to parse into accurate financial data.

However, Because of the large number of these institutions and this difficulty in tracking their positions, they represent a significant, yet hidden, market force. In an effort to widen our ownership coverage and provide greater transparency, we are testing various ways to expose these owners in an accurate manner. This early version of the crawler simply identifies mentions of companies in the N-Q forms.

Limitations:

  • We only list underlying securities (the ordinary shares), even though the actual security held might be a derivative or a related bond issue. For example, although the institution is shown on this security page ( BVSN / BroadVision, Inc. ), the institution may actually own a related security such as a preferred share or a bond. To find out the exact security, click on the institution link and then follow the link to the actual "N-Q".
  • We only list fund sponsors as institutions, even though the security might be held within a fund operated by the listed institution.. For example, the institution listed in the table as the owner is probably a sponsor of a family of ETFs or mutual funds. If so, then this security is owned by a fund or several funds within the family, and not directly owned by the listed institution. The crawler is not yet able to place these holdings within the individual funds. Atain, you must review the actual filing to see the detail.

These limitations are significant but we believe that the increased transparency outweights the limitations. Future revisions of the crawler will resolve these limitations. Use this information at your own risk!

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

Related News Stories

10 Tech Stocks That Aren’t Worth the Risk

2018-04-20 investorplace
While the tech-heavy Nasdaq 100 is up 24% over the past year, it’s only up 3.7% year to date. (49-0)

BRIEF-Broadvision Inc Says Peter Chu Resigned As CFO

2018-03-09 reuters
* BROADVISION SAYS ON MARCH 7 PETER CHU ANNOUNCED HIS RESIGNATION AS CFO - SEC FILING (2-0)

CUSIP: 111412706